COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- Crackdown on private sector graft enhanced
- Foreign mediators play crucial role in dispute resolution
- Nation marks 50 years of relations with Mozambique
- European students explore modern China through BFSU program
- From Belgium to studying Chinese medicine in Yunnan: I found my answer at the South Expo
- Shanghai Disneyland to open new immersive, interactive exhibition
